Management of Opioid Use Disorder According to DSM-5 Criteria
Clinicians should offer or arrange medication-assisted treatment with buprenorphine or methadone combined with behavioral therapies for patients meeting DSM-5 criteria for opioid use disorder. 1, 2
Diagnosis Using DSM-5 Criteria
Opioid use disorder is defined as a problematic pattern of opioid use causing clinically significant impairment or distress, with at least 2 of 11 criteria occurring within a 12-month period 1, 3. The diagnostic threshold of 2 or more criteria was selected to maximize agreement with DSM-IV prevalence while identifying all cases meriting intervention, including milder presentations in primary care 3.
Important exception: For patients using opioids under medical supervision (prescribed stimulants, opioids, sedatives), tolerance and withdrawal alone do not indicate OUD if no other criteria are present—these represent normal physiological adaptations 3.
Severity Classification
- Mild: 2-3 criteria
- Moderate: 4-5 criteria
- Severe: 6 or more criteria 3
First-Line Treatment: Medication-Assisted Treatment (MAT)
Preferred Medications
Both methadone and buprenorphine are now considered equally effective first-line options based on substantial evidence showing similar effectiveness in reducing opioid use and adverse events 4. This represents a key update from earlier guidelines.
Buprenorphine:
- Partial opioid agonist with high μ-receptor binding affinity
- Can be prescribed in office-based settings by physicians with DEA waiver (8 hours training required) 1
- FDA-approved for patients ≥16 years old 5
- Available as sublingual tablet/film, transdermal patch, or 6-month implant
- Safer profile: ceiling effect on respiratory depression, lower overdose risk 6
- Fewer drug-drug interactions compared to methadone 7
Methadone:
- Full opioid agonist with long half-life
- Requires specialized methadone clinic for dispensing (federal regulations restrict access for patients <18 years) 5
- Highest treatment retention rates across studies 7
- Requires careful monitoring: prolongs QTc interval, risk of arrhythmia 7
- More clinically significant drug interactions, particularly with antiretroviral therapy 7
Naltrexone (extended-release injectable):
- Opioid antagonist, blocks effects of opioids
- Second-line option for highly motivated non-pregnant adults who can maintain abstinence before induction 1, 2
- No risk of misuse or diversion 5
- May benefit patients with co-occurring alcohol use disorder 5
- Requires adherence to monthly injections
Behavioral Therapies
Psychosocial interventions should be offered as adjunctive treatment but not made mandatory 4. Behavioral therapies combined with medications reduce opioid misuse, increase retention during maintenance therapy, and improve compliance after detoxification 1, 2. Evidence-based options include cognitive behavioral therapy (CBT) 2.
Treatment Initiation and Monitoring
Buprenorphine Induction (Emergency Department Protocol)
Critical timing: Administer buprenorphine only to patients in active opioid withdrawal to avoid precipitated withdrawal 6.
Withdrawal assessment timing:
- Short-acting opioids (heroin, oxycodone): >12 hours since last use
- Long-acting formulations (OxyContin): >24 hours
- Methadone maintenance: >72 hours (consider methadone instead) 6
Use Clinical Opiate Withdrawal Scale (COWS):
- COWS <8 (mild): No buprenorphine indicated, reassess in 1-2 hours
- COWS ≥8 (moderate-severe): Give buprenorphine 4-8 mg sublingual based on severity 6
Target dose: 16 mg sublingual total for most patients on day 1, reassess after 30-60 minutes 6
Ongoing Monitoring
Assessment schedule:
- 2 weeks: Evaluate craving and drug use response to medication 8
- 1-4 weeks: Assess benefits and harms after starting or dose escalation 9, 1
- 3 months: Evaluate OUD remission status and benefits/harms of continued therapy 9, 1, 8
- 6 months: Remission assessment 8
- 12 months and beyond: Ongoing remission evaluation 8
Required monitoring tools:
- State Prescription Drug Monitoring Program (PDMP) data: Review when starting therapy and periodically (every prescription to every 3 months) 9
- Urine drug testing: Before starting therapy and at least annually 9
- Avoid concurrent benzodiazepines whenever possible (risk of fatal respiratory depression) 9, 2, 1
Special Populations
Pregnant Women
- Offer buprenorphine (without naloxone) or methadone—both associated with improved maternal outcomes 2
- Continue daily MAT dose throughout labor to prevent withdrawal 10
- Consider dividing dose into 2-3 daily doses for improved pain control 10
Adolescents
- Opioid use disorder has low spontaneous remission rates but patients can recover with treatment 5
- Offer medication-assisted treatment to adolescents ≥16 years with severe OUD 5
- Federal regulations prohibit most methadone programs from admitting patients <18 years 5
Patients on Buprenorphine with Inadequate Pain Control
- Increase buprenorphine dose in divided doses (4-16 mg every 8 hours) 7
- Consider switching to buprenorphine transdermal formulation (bypasses hepatic first-pass metabolism) 7
- Add long-acting potent opioid (fentanyl, morphine, hydromorphone) if maximal buprenorphine reached 7
- If usual doses ineffective, trial higher doses of additional opioid with close monitoring (buprenorphine's high receptor affinity may block lower doses) 7
- Transition to methadone maintenance if above strategies fail 7
Critical Pitfalls to Avoid
- Never use opioid agonist/antagonists (nalbuphine, butorphanol) in opioid-dependent patients—can precipitate withdrawal 10
- Avoid withdrawal management as standalone intervention—associated with poor outcomes 4
- Do not withhold MAT due to concurrent substance use—continue treatment and address polysubstance use 4
- Never abruptly discontinue benzodiazepines—taper by 25% every 1-2 weeks to avoid seizures, delirium tremens, or death 2, 1
- When tapering both opioids and benzodiazepines, taper opioids first (benzodiazepine withdrawal more dangerous; opioid tapering can increase anxiety) 2, 1
Harm Reduction Integration
Offer naloxone for overdose prevention to all patients with OUD 6, 2. Provide overdose prevention education and take-home naloxone kits at discharge 6. Incorporate evidence-based harm reduction services along the continuum of care 4.